Email updates

Keep up to date with the latest news and content from Infectious Agents and Cancer and BioMed Central.

This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research

Open Access Poster presentation

Survival and prognosis of HIV-associated non-Hodgkin-lymophma in the era of combined anti-retroviral therapy, a European multi-cohort study

J Bohlius

  • Correspondence: J Bohlius

Author Affiliations

for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Infectious Agents and Cancer 2009, 4(Suppl 2):P10  doi:10.1186/1750-9378-4-S2-P10

The electronic version of this article is the complete one and can be found online at: http://www.infectagentscancer.com/content/4/S2/P10


Published:17 June 2009

© 2009 Bohlius; licensee BioMed Central Ltd.

Background

Since the introduction of combined anti-retroviral therapy (cART), survival of patients with HIV-associated NHL improved dramatically. We examined survival and HIV-related prognostic factors of patients with HIV-related NHL in the era of cART within the framework of a large European multi-cohort collaborative study.

Methods

We analyzed the data of HIV-infected adult patients (age > 16 years) who developed a NHL after January 1, 1998. We included patients who were cART naïve at inclusion and started cART after January 1, 1998. Only patients who started cART at some point during lifetime were included in the present analysis. cART was defined as regimen with at least three antiretroviral drugs. Patients had to have at least one CD4 cell count measurement after January 1, 1998, and before or within 7 days of NHL diagnosis. Survival and prognostic factors were estimated using crude and adjusted Weibull models, with random-effects accounting for heterogeneity between cohorts.

Results

We observed 67,659 HIV-infected patients. Of 1,176 patients who developed NHL, 847 (72%) NHL patients from 22 collaborating cohorts across Europe were included in the present analysis. The 329 (28%) NHL patients who did not meet the inclusion criteria outlined above were excluded. After 1 year, 66 percent (95% CI 63%–70%) of patients with NHL other than Primary Brain Lymphoma (PBL) and 54 percent (95% CI 43%–65%) of patients with PBL were alive. Negative predictive factors for survival were diagnosis of PBL, low CD4 cell count nadir and history of injection drug use.

Conclusion

In the era of cART two-thirds of patients diagnosed with HIV-related NHL other than PBL survive for longer than 1 year after diagnosis. Survival is poorer in patients diagnosed with PBL.

More advanced immunodeficiency is the dominant prognostic factor for mortality in patients with HIV-related NHL.